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Aberdeen, UK; and 4Department of Renal Medicine, Royal Inﬁrmary of Edinburgh, Edinburgh, UKIntroduction: Stroke rate and mortality are greater in individuals with end-stage renal disease (ESRD) than
in those without ESRD. We examined discrepancies in stroke care in ESRD patients and their inﬂuence on
mortality.
Methods: This is a national record linkage cohort study of hospitalized stroke individuals from 2005 to
2013. Presentation, measures of care quality (admission to stroke unit, swallow assessment, antith-
rombotics, or thrombolysis use), and outcomes were compared in those with and without ESRD after
propensity score matching (PSM). We examined the effect of being admitted to a stroke unit on survival
using Kaplan-Meier and Cox survival analyses.
Results: A total of 8757 individuals with ESRD and 61,367 individuals with stroke were identiﬁed. ESRD
patients (n ¼486) experienced stroke over 34,551.9 patient-years of follow-up; incidence rates were 25.3
(dialysis) and 4.5 (kidney transplant)/1000 patient-years. After PSM, dialysis patients were less likely to be
functionally independent (61.4% vs. 77.7%; P < 0.0001) before stroke, less frequently admitted to stroke
units (64.6% vs. 79.6%; P < 0.001), or to receive aspirin (75.3% vs. 83.2%; P ¼ 0.01) than non-ESRD stroke
patients. There were no signiﬁcant differences in management of kidney transplantation patients. Stroke
with ESRD was associated with a higher death rate during admission (dialysis 22.9% vs.14.4%, P ¼ 0.002;
transplantation: 19.6% vs. 9.3%; P ¼ 0.034). Managing ESRD patients in a stroke unit was associated with a
lower risk of death at follow-up (hazard ratio: 0.68; 95% conﬁdence interval: 0.550.84).
Conclusion: Stroke incidence is high in ESRD. Individuals on dialysis are functionally more dependent
before stroke and less frequently receive optimal stroke care. After a stroke, death is more likely in ESRD
patients. Acute stroke unit care may be associated with lower mortality.
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chronic kidney disease (CKD) is incorporated into risk
prediction algorithms used to guide preventative
treatments for cardiovascular disease.2,3 Risk is greatest
in end-stage renal disease (ESRD), which is approxi-
mately 5 to 20 times that of the age-matched controlled
general population,4,5 and treatments such as dialysis
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2018; published online 27 April 2018increase risk further.6,7 Risk of stroke is reported to be
10 time more common in ESRD,8,9 yet case mix pre-
sentation, management, and outcomes of stroke in in-
dividuals with ESRD remains poorly understood.
In ESRD, provision of evidence-based management
of cardiovascular disease and stroke prevention is
hindered10–12 by limited evidence of beneﬁt with in-
terventions such as statins13 or anticoagulation.14
Advanced CKD is a common exclusion criterion in
trials that target cardiovascular risk.15 Individuals with
ESRD are typically admitted to renal units when hos-
pitalized for intercurrent illness.10,16 This could affect
access to stroke unit care and treatments shown to
improve stroke outcomes.17
We assessed the incidence of stroke in ESRD and
if the presence of ESRD inﬂuenced presentation,Kidney International Reports (2018) 3, 1064–1076
MD Findlay et al.: Inequalities in Stroke Care in ESRD CLINICAL RESEARCHmanagement, and outcome of stroke by merging data
from the Scottish Renal Registry and Scottish Stroke
Care Audit. We hypothesized that key care quality
indicators in stroke would be less commonly achieved
in those with ESRD compared with those without
ESRD.
METHODS
We performed a national data linkage study using
data within the Scottish Renal Registry (SRR), Scottish
Stroke Care Audit (SSCA), Scottish Morbidity Records
(SMR), and the National Records of Scotland. We used
propensity score matching (PSM) and assessed case
mix presentation, measures of care quality, and out-
comes after stroke in individuals with and without
ESRD.
Data Sets
SRR is a nation-wide data set, contributed to by all
renal units in Scotland.18,19 All patients who receive
renal replacement therapy (RRT) for ESRD are
included. The SRR records patient demographics, renal
replacement modality, clinical measurements, labora-
tory results, and cause of death.
SSCA monitors performance of stroke care against
guideline-derived standards throughout Scotland. Data
held by the SSCA includes all cases of stroke and
transient ischemic attack admitted to hospital. Ascer-
tainment of stroke cases in the SSCA is carried out by
trained audit coordinators supported by stroke clini-
cians. Data are collected on demographics, case mix at
presentation, stroke classiﬁcation, use of brain imaging,
antithrombotic medication, stroke unit care, and
discharge outcomes. This data set has provided
coverage of all hospitals managing acute stroke
since 2005.
SMR01 has been collecting data on all surgical and
medical hospital admissions since 1968. Since 1989,
SMR01 has been used to plan hospital ﬁnances to
ensure a high completion rate.
The National Records of Scotland is a department of
Scottish Government, responsible for registration of life
events, including deaths.
All 4 datasets were linked, from January 1, 2005 to
December 31, 2013. We included only adults (16 years
or older at stroke) in our analyses. Supplementary
Figures S1 and S2 demonstrate the construction of the
linked data sets for analysis.
Deﬁnitions
Stroke
Only cases of conﬁrmed stroke as a ﬁnal diagnosis were
included. The SMR01 was interrogated for International
Classiﬁcation of Diseases (ICD-10) codes for strokeKidney International Reports (2018) 3, 1064–1076(I60, I61, I62.9, I63, and I64). All stroke diagnoses were
ordered by date of stroke from January 1, 2005 and the
ﬁrst recorded stroke date, with the source of diagnosis
recorded. In cases in which SMR01 and SSCA diagnoses
overlapped, the SSCA was used as the source.
End-Stage Renal Disease
All patients commencing RRT for ESRD in Scotland are
recorded within the SRR. ESRD is a diagnosis deter-
mined by the clinician initiating RRT or by continued
use of RRT for >90 days for acute kidney injury
without renal recovery.
Modality of RRT
We considered 3 groups of ESRD patients; (i) all patients
with ESRD regardless of RRT modality, (ii) patients
receiving dialysis (either hemodialysis [HD] or perito-
neal dialysis [PD] at the start of study, or who began HD
or PD as their ﬁrst RRT modality during the study), and
(iii) individuals with a kidney transplant (either at
commencement of the study or who were transplanted
during the study de novo or after a period of dialysis).
Baseline Characteristics
The SMR01 was interrogated from January 1, 1981 to
December 31, 2013 for presence of ICD-10 codes related
to atrial ﬁbrillation and/or ﬂutter (I48), ischemic heart
disease (I21, 24, 24.8, I24.9, I25, I25.1, I25.2, I25.5, and
I25.8), diabetes mellitus (E10 and E11), and hyperten-
sion (I10 and I15). To prevent overlap of diagnoses, ICD
codes for stroke (as previously described) were pulled
from 1981 until date of the ﬁrst stroke in individuals
who experienced stroke or until December 31, 2013 in
individuals who did not have a stroke.
Using Scottish Government urban-rural and socio-
economic classiﬁcations based on patient postcode, we
subdivided patients into the most or least deprived and
urban or rural as described elsewhere.20 We used the
postcode at commencing RRT in patients on RRT or
with stroke for the non-ESRD stroke population.
SSCA Auditable Standards
SSCA annually reports standards of stroke care
compared with audited targets, speciﬁcally, the per-
centage with access to a stroke unit within 1 day of
admission, brain imaging within 24 hours of admission,
swallow screen on day of admission, aspirin within 1
day of admission (if the index stroke was ischemic),
and thrombolysis within 1 hour of arrival to hospital.
We present 2 forms of data regarding these standards.
First, the percentage of cases that received the
following at any point during their admission included
stroke unit care, brain imaging, swallow screen,
aspirin, or thrombolysis. Second, we reanalyzed, using
date and time of admission to hospital and date and
time of each care standard, to determine time-speciﬁc
outcomes as per SSCA standards.1065
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Using the national death records, we determined
vitality status until September 25, 2015 for all persons.
Death during stroke admission and vitality status at
end of follow-up are presented. When exploring the
impact of stroke care on mortality, we omitted cases of
stroke diagnosed only at death and analyzed both
ESRD and non-ESRD populations based on the source
of the initial diagnosis: SSCA or SMR01. Causes of
death for all patients are presented as per ICD-10
coding rules in Supplementary Tables S1 to S3.
Statistical Analyses
Data cleaning and analyses were performed using SAS,
version 9.4 (SAS Institute Inc, Cary, NC). Graphs were
produced using Stata version 14.1 (Statacorp, College
Station, TX).
Incidence rates are expressed per 1000 patient-years
and calculated using the number of stroke events
divided by the follow-up time. Follow-up time is
calculated using date of study entry (January 1, 2005)
or start of RRT for ESRD until the date of stroke, death,
change of renal replacement modality, or end of study.
We compared patient demographics split by the
source of stroke diagnosis: SSCA versus SMR01 and
stroke versus no stroke. Demographic values are pre-
sented as mean  SD or median (interquartile range
[IQR]), and comparison between groups was assessed
using the t-test, Mann-Whitney U test, or the c2 test as
appropriate. To account for differences in cohort size,
we compared pre- and postmatching demographics
using standardized differences.
Propensity Score Matching
Individuals with ESRD and stroke are more likely to
have comorbidities than individuals without. To
reduce the potential for confounding, we performed
propensity score matching (PSM) for all ESRD patients,
then individually for each of those on dialysis and with
a renal transplant. Matching was based on factors
predictive of stroke or outcome. Speciﬁcally, we
matched on age, sex, deprivation and rurality status,
and medical history of stroke, ischemic heart disease,
hypertension, diabetes, and atrial ﬁbrillation. We
matched using nearest neighbour matching, at a ratio
of 5:1. Data were tabulated for all ESRD, dialysis, and
kidney transplantation cohorts. Data were presented
before and after PSM in each case, with comparison
between groups using the Mann-Whitney U or the c2
tests as appropriate. Because our primary aim was to
directly compare cohorts, missing data were not
imputed, but rather were presented within each table.
PSM was performed using the computing environment
R, MatchIt package (R Foundation, Vienna, Austria).211066Survival analyses were performed using the Kaplan-
Meier estimator and Cox proportional hazard model.
We assessed differences between survival probabilities
after stroke in dialysis, kidney transplantation, and
non-ESRD stroke populations. Finally, to explore
effects of care on outcome, we used admission to a
stroke unit as a surrogate for optimal stroke care in
ESRD (adjusted for age, sex, use of dialysis, previous
diabetes, ischemic heart disease, hypertension, and
atrial ﬁbrillation) to examine its impact on death at
follow-up. The strengthening the reporting of obser-
vational studies in epidemiology (STROBE) guidelines
were followed in this observational study
(Supplementary Figure 4).
Ethical Approval
The data sets used work within the National Health
Service Code of Practice on Protecting Patient Conﬁ-
dentiality, incorporating requirements of statutes and
common law including the Data Protection, Human
Rights, and the Adults with Incapacity (Scotland) Acts.
Access and use of data were approved following Na-
tional Services Scotland proportionate governance re-
view by the Privacy Advisory Committee of
Information Services Division, National Health Service
Scotland Reference 55/14.
RESULTS
ESRD Stroke Incidence Rate and Stroke Record
Source
There were 8757 individuals aged 16 or older in the
SRR from January 1, 2005 to December 31, 2013. A total
of 6749 were receiving dialysis at study entry, and
3699 had a kidney transplant at entry or were trans-
planted during follow-up. A total of 486 (5.5%)
individuals experienced stroke during 34,551.9
patient-years of follow-up. The stroke incidence rate
per 1000 patient-years for all individuals with ESRD
was 14.1; for individuals on dialysis, it was 25.3 (26.7
for HD and 17.3 for PD), and for individuals with a
kidney transplant, it was 4.5.
Of the ﬁrst recorded stroke during the study period,
230 (47.3%) were recorded in the SSCA, 219 (45.1%) in
the SMR01, and 37 (7.6%) as a primary cause of death
(having not been diagnosed prior to death). No signiﬁ-
cant differences existed in baseline demographics be-
tween individuals with ESRD and stroke in the SMR01
database compared with the those in the SSCA database
(Table 1).
Demographics in ESRD: Stroke Versus No
Stroke
In all individuals with ESRD, there were differences
between those who experienced stroke and those whoKidney International Reports (2018) 3, 1064–1076
Table 1. Baseline demographics of all end-stage renal disease
patients with stroke, split by source of diagnosis
Variable
SSCA stroke
(n [ 230)
SMR01 stroke
(n [ 219) P value
Age at stroke, yr, median (IQR) 71 (13) 71 (17) 0.406
Sex
Female (%) 111 (48.3) 93 (42.5)
Male (%) 119 (51.7) 126 (57.5) 0.220
Primary renal diagnosis group
Glomerulonephritis 36 (15.7) 31 (14.2) 0.692
Interstitial disease 48 (20.9) 46 (21.0) 1.000
Multisystem 53 (23.0) 46 (21.0) 0.649
Diabetic nephropathy 57 (24.8) 60 (27.4) 0.591
Other 36 (15.7) 36 (16.4) 0.898
Urban-rural
Rural 34 (14.8) 35 (16.0)
Urban 196 (85.2) 184 (84.0) 0.794
SIMD
Least deprived 171 (74.4) 154 (70.3)
Most deprived 59 (25.7) 65 (29.7) 0.344
Era of stroke
20052006 54 (23.5) 88 (40.2)
20072008 50 (21.7) 44 (20.1)
20092010 43 (18.7) 48 (21.9)
20112013 83 (36.1) 39 (17.8) <0.001
Medical history
Atrial ﬁbrillation 21 (9.1) 30 (13.7) 0.139
Ischemic heart disease 81 (35.2) 86 (39.3) 0.381
Previous stroke 20 (8.7) 24 (11.0) 0.432
Diabetes 90 (39.1) 90 (41.1) 0.701
Hypercholesterolemia 41 (17.8) 34 (15.5) 0.530
Obesity 15 (6.5) 14 (6.4) 1.000
HBP 171 (74.5) 164 (74.9) 0.914
Clinical variables, median (IQR)
Systolic BP, mm Hg 146.0 (30.0) 141.0 (28.8) 0.475
Diastolic BP, mm Hg 69.8 (22.0) 68.5 (17.5) 0.894
Weight, kg 68.4 (28.0) 71.8 (23.1) 0.213
Laboratory variables, median (IQR)
Hemoglobin, g/l 11.5 (1.8) 11.4 (1.7) 0.825
Albumin, mmol/l 36.0 (7.0) 37.8 (6.0) 0.171
Serum phosphate, mmol/l 1.45 (0.61) 1.48 (0.62) 0.449
Adjusted calcium, mmol/l 2.33 (0.2) 2.35 (0.2) 0.220
ESA use
Death at follow-up 191 (83.0) 205 (93.6) <0.001
ESA, erythropoietin-stimulating agent; BP, blood pressure; HBP, high blood pressure;
IQR, interquartile range; SIMD, Scottish Index of Multiple Deprivation; SMR01, Scottish
Morbidity Records 01; SSCA, Scottish Stroke Care Audit.
Data are presented as no. (%).
Table 2. Baseline demographics of all end-stage renal disease
patients, no stroke versus stroke
Variable
No stroke
(n [ 8271)
Stroke
(n [ 486) P value
Age at ﬁrst RRT, yr, median (IQR) 56.4 (30.6) 66.3 (19.3) <0.0001
Sex (%)
Female 3494 (41.7) 221 (45.5)
Male 4893 (58.3) 265 (54.5) 0.098
Primary renal diagnosis group
Glomuleronephritis 1532 (18.5) 70 (14.4) 0.022
Interstitial disease 2205 (26.7) 102 (21.0) 0.006
Multisystem 1680 (20.3) 114 (23.5) 0.105
Diabetic nephropathy 1463 (17.7) 122 (25.1) <0.0001
Other 1379 (16.7) 78 (16.1) 0.754
Missing 12 (0.1) 0
Urban-rural
Rural 1380 (16.7) 75 (15.4)
Urban 6891 (83.3) 411 (84.6) 0.491
SIMD
Least deprived 6129 (74.1) 356 (73.3)
Most deprived 2142 (25.9) 130 (26.8) 0.670
Medical history
Atrial ﬁbrillation 502 (6.1) 52 (10.7) <0.001
Ischemic heart disease 2519 (30.5) 176 (36.2) 0.012
Stroke 272 (3.3) 48 (9.9) <0.001
Diabetes 2468 (29.8) 193 (39.7) <0.001
Hypercholesterolemia 1053 (12.7) 80 (16.5) 0.022
Obesity 464 (5.6) 31 (6.4) 0.480
HBP 5894 (71.3) 361 (74.3) 0.233
Clinical variables, median (IQR)
Systolic BP, mm Hg 138 (29.0) 142 (30.0) <0.001
Diastolic BP, mm Hg 72 (18.0) 69 (20.0) 0.077
Weight, kg 72.7 (23.0) 70.3 (25.6) 0.008
Laboratory variables
Hemoglobin, g/l 11.7 (1.9) 11.45 (1.5) <0.001
Albumin, mmol/l 38.0 (7.0) 37.0 (7.0) <0.001
Serum phosphate, mmol/l 1.35 (0.6) 1.46 (0.6) <0.001
Adjusted calcium, mmol/l 2.37 (0.2) 2.35 (0.2) 0.004
ESA use 4873 (58.9) 268 (55.1) 0.107
Death at follow-up 4188 (50.6) 433 (89.1) <0.001
ESA, erythropoietin-stimulating agent; BP, blood pressure; HBP, high blood pressure;
IQR, interquartile range; RRT, renal replacement therapy; SIMD, Scottish Index of
Multiple Deprivation.
Data are presented as no. (%).
MD Findlay et al.: Inequalities in Stroke Care in ESRD CLINICAL RESEARCHdid not (Table 2). Individuals with stroke were older at
commencing RRT, more likely to have atrial ﬁbrilla-
tion, a history of stroke, and diabetes. In the dialysis
group, previous ischemic heart disease was not asso-
ciated with stroke, whereas higher serum phosphate
was associated with stroke. In the transplantation
group, the inverse was true; previous ischemic heart
disease and lower serum phosphate were associated
with stroke. Further details are outlined in
Supplementary Tables S4 and S5.Kidney International Reports (2018) 3, 1064–1076Demographics: SSCA Stroke in the ESRD
Population Versus SSCA Stroke in the
Non-ESRD Population
We identiﬁed 61,367 individuals registered in the SSCA
with stroke during our study period. A total of 280
(0.5%) individuals in the SSCA data set were on RRT
for ESRD. Compared with the background population,
individuals with ESRD developed stroke at a younger
age, and had a greater prevalence of previous ischemic
heart disease, hypertension, and diabetes (Table 3).
Similar results were found in individuals on dialysis
(Table 4). In the renal transplantation population, there
were differences in age, sex, hypertension, and dia-
betes status (Table 5). PSM removed all demographic
differences (Tables 3–5).1067
Table 3. Demographics, presentation, management, and outcomes after stroke from the Scottish Stroke Care Audit showing data before and
after propensity score matching for all patients with end-stage renal disease
Variable
Non-ESRD population
(n [ 61,087)
ESRD population
(n [ 280)
Standardized
differencea/P value
Propensity-matched
non-ESRD population
(n [ 1,395)
Propensity-matched
renal population
(n [ 279)
Standardized
differencea/P value
Patient demographics
Age at stroke, yr, median (IQR) 76 (17.0) 71 (16.0) 0.48 70 (17.0) 70 (17.0) 0.01
Female 31,368 (51.4) 140 (50.0) 0.03 713 (51.1) 139 (49.8) 0.03
Rural 10,015 (16.4) 41 (14.6) 0.05 187 (13.4) 41 (14.7) 0.04
Deprived 29,709 (48.6) 138 (49.3) 0.01 713 (51.1) 138 (49.5) 0.03
Previous AF 5019 (8.2) 26 (9.3) 0.03 102 (7.3) 26 (9.3) 0.07
Previous CeVD 3555 (5.8) 27 (9.6) 0.14 111 (8.0) 26 (9.3) 0.05
Previous IHD 12,025 (19.7) 97 (34.6) 0.33 486 (34.8) 96 (34.4) 0.01
Previous hypertension 25,818 (42.3) 208 (74.3) 0.66 1073 (76.9) 207 (74.2) 0.06
Previous diabetes 8536 (14.0) 113 (40.4) 0.61 531 (38.1) 112 (40.1) 0.04
Case mix
Independent in ADLs before admission 47,184 (77.2) 179 (63.9) <0.0001 1096 (78.6) 178 (63.8) <0.0001
Missing 5109 (8.4) 37 (13.2) 134 (9.6) 37 (13.3)
Living alone before admission 22,065 (36.1) 64 (22.9) <0.0001 430 (30.8) 64 (22.9) 0.025
Missing 4453 (7.3) 36 (12.9) 124 (8.9) 36 (12.9)
Talking at ﬁrst assessment 42,795 (70.1) 196 (70.0) 0.386 1020 (73.1) 195 (69.9) 0.678
Missing 3707 (6.1) 26 (9.3) 93 (6.7) 26 (9.3)
Orientated at ﬁrst assessment 35,846 (58.7) 160 (57.1) 0.789 895 (64.2) 159 (57.0) 0.094
Missing 5325 (8.7) 35 (12.5) 128 (9.2) 35 (12.5)
Able to lift arms at ﬁrst assessment 35,622 (58.3) 178 (63.6) 0.013 833 (59.7) 178 (63.8) 0.092
Missing 4817 (7.9) 29 (10.4) 123 (8.8) 29 (10.4)
Able to walk on ﬁrst assessment 23,732 (38.9) 95 (33.9) 0.197 561 (40.2) 95 (34.1) 0.091
Missing 5529 (9.1) 34 (12.1) 141 (10.1) 34 (12.2)
Index stroke
Ischemic 51,606 (84.5) 255 (91.1) 1186 (85.0) 245 (91.0)
Hemorrhagic 6954 (11.4) 23 (8.2) 0.063 140 (10.0) 23 (8.2) 0.277
Missing 2527 (4.1) 2 (0.7) 69 (5.0) 2 (0.7)
Admission source
Acute hospital 1984 (3.3) 22 (7.9) <0.001 31 (2.2) 21 (7.5) <0.0001
Sheltered/care home 2758 (4.5) 2 (0.7) <0.001 41 (2.9) 2 (0.7) 0.035
Home 54,613 (89.4) 240 (85.7) 0.250 1277 (91.5) 240 (86.0) 0.050
Rehab/other 904 (1.5) 7 (2.5) 0.133 31 (2.2) 7 (2.5) 0.661
Missing 828 (1.4) 9 (3.2) 15 (1.1) 9 (3.2)
Management
Admitted to stroke unit 47,619 (78.0) 189 (67.5) 0.002 1110 (79.6) 188 (67.4) <0.001
Missing 1415 (2.3) 16 (5.7) 24 (1.7) 16 (5.7)
Thrombolysis: IS only 2487 (4.8) 10 (3.9) 0.649 54 (4.6) 10 (3.9) 0.863
Missing 25,009 (40.9) 126 (45) 560 (40.1) 125 (44.8)
Aspirin: IS only 43,194 (83.7) 190 (74.5) <0.001 991 (83.6) 190 (74.8) 0.002
Missing 601 (1.0) 4 (1.4) 13 (0.9) 4 (1.4)
Swallow screen 48,692 (79.7) 214 (76.4) 0.191 1098 (78.7) 213 (76.3) 0.433
Missing 2519 (4.1) 13 (4.6) 59 (4.2) 13 (4.7)
Brain imaging 59,680 (97.7) 278 (99.3) 0.257 1365 (97.9) 277 (99.3) 0.754
Missing 284 (0.5) 0 14 (1.0) 0
Duration of admission (IQR) 13 (37.0) 16 (38.0) 0.211 12 (33.0) 16 (38.0) 0.079
Discharge destination
NHS bed 3969 (6.5) 42 (15.0) <0.0001 66 (4.7) 42 (15.1) <0.0001
Care home 6390 (10.5) 15 (5.4) 0.003 100 (7.2) 15 (5.4) 0.302
Home/sheltered 39,125 (64.1) 153 (54.6) <0.001 979 (70.2) 152 (54.5) <0.0001
Other 782 (1.3) 4 (1.4) 0.786 25 (1.8) 4 (1.4) 0.806
Died 9694 (15.9) 62 (22.1) 0.007 188 (13.5) 62 (22.2) 0.001
Missing 1127 (1.8) 4 (1.4) 37 (2.7) 4 (1.4)
Death at follow-up 33,169 (54.3) 229 (81.8) <0.0001 676 (48.5) 228 (81.7) <0.0001
ADL, activities of daily living; AF, atrial ﬁbrillation; CeVD, Cerebrovascular Disease; IHD, ischemic heart disease; IQR, interquartile range; IS, ischemic stroke; NHS, National Health
Service.
aStandardized difference: difference in means or proportions divided by SE; imbalance defined as absolute values >0.20.
Data are presented as no. (%).
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Table 4. Demographics, presentation, management, and outcomes after stroke form the Scottish Stroke Care Audit showing data before and
after propensity score matching for individuals on dialysis for end-stage renal disease.
Variable
Non-ESRD population
(n [ 61,087)
Dialysis population
(n [ 224)
Standardized
differencea/P value
Propensity-matched
non-ESRD population
(n [ 1115)
Propensity-matched
dialysis population
(n [ 223)
Standardized
differencea/P value
Patient demographics
Age at stroke, yr (IQR) 76 (17.0) 72 (16.0) 0.37 73 (15.0) 72 (16.0) 0.09
Female 31,368 (51.4) 119 (53.1) 0.04 613 (55.0) 118 (52.9) 0.04
Rural 10,015 (16.4) 35 (15.6) 0.02 169 (15.2) 35 (15.7) 0.01
Deprived 29,709 (48.6) 108 (48.2) 0.01 542 (48.6) 108 (48.4) 0.00
Previous AF 5019 (8.2) 22 (9.8) 0.05 107 (9.6) 22 (9.9) 0.01
Previous CeVD 3555 (5.8) 22 (9.8) 0.14 88 (7.9) 21 (9.4) 0.05
Previous IH 12,025 (19.7) 82 (36.6) 0.37 435 (39.0) 81 (36.3) 0.06
Previous hypertension 25,818 (42.3) 167 (74.6) 0.66 872 (78.2) 166 (74.4) 0.09
Previous diabetes 8536 (14.0) 93 (41.5) 0.63 445 (39.9) 92 (41.3) 0.03
Case mix
Independent in ADLs before admission 47,184 (77.2) 138 (61.6) <0.0001 886 (77.7) 137 (61.4) <0.0001
Missing 5109 (8.4) 28 (12.5) 118 (10.6) 28 (12.6)
Living alone before admission 22,065 (36.1) 52 (23.2) <0.001 346 (31.0) 52 (23.3) 0.046
Missing 4453 (7.3) 27 (12.1) 95 (8.5) 27 (12.1)
Talking at ﬁrst assessment 42,795 (70.1) 159 (71.0) 0.377 797 (71.5) 158 (70.9) 0.856
Missing 3707 (6.1) 19 (8.5) 74 (6.6) 19 (8.5)
Orientated at ﬁrst assessment 35,846 (58.7) 13 (58.0) 0.824 686 (61.5) 129 (57.9) 0.508
Missing 5325 (8.7) 25 (11.2) 101 (9.1) 25 (11.2)
Able to lift arms at ﬁrst assessment 35,622 (58.3) 141 (63.0) 0.080 650 (58.3) 141 (63.2) 0.125
Missing 4817 (7.9) 21 (9.4) 99 (8.9) 21 (9.4)
Able to walk on ﬁrst assessment 23,732 (38.9) 69 (30.8) 0.026 420 (37.7) 69 (30.9) 0.068
Missing 5529 (9.1) 26 (11.6) 118 (10.6) 26 (11.7)
Index stroke
Ischemic 51,606 (84.5) 203 (90.6) 947 (84.9) 202 (90.6)
Hemorrhagic 6954 (11.4) 19 (8.5) 122 (10.9) 19 (8.5)
Missing 2527 (4.1) 2 (0.9) 0.145 46 (4.1) 2 (0.9) 0.239
Admission source
Acute hospital 1984 (3.3) 22 (9.8) <0.0001 27 (2.4) 21 (9.4) <0.0001
Sheltered/care home 2758 (4.5) 2 (0.9) 0.005 30 (2.7) 2 (0.9) 0.147
Home 54613 (89.4) 186 (83.0) 0.019 1020 (91.5) 186 (83.4) 0.001
Rehab/Other 904 (1.5) 7 (3.1) 0.047 18 (1.6) 7 (3.1) 0.166
Missing 828 (1.4) 7 (3.1) 20 (1.8) 7 (3.1)
Management
Admitted to stroke unit 49,619 (78.0) 145 (64.7) <0.001 888 (79.6) 144 (64.6) <0.001
Missing 1415 (2.3) 16 (7.1) 27 (2.4) 16 (7.2)
Thrombolysis: IS only 2487 (4.8) 7 (3.5) 0.496 47 (5.0) 7 (3.5) 0.568
Missing 25,009 (40.9) 100 (44.6) 439 (39.4) 99 (44.4)
Aspirin: IS only 43,194 (83.7) 152 (74.9) 0.002 788 (83.2) 152 (75.3) 0.010
Missing 601 (1.0) 3 (1.3) 11 (1.0) 3 (1.3)
Swallow screen 48,692 (79.7) 173 (77.2) 0.315 903 (81.0) 172 (77.1) 0.229
Missing 2519 (4.1) 9 (4.0) 38 (3.4) 9 (4.0)
Brain imaging 59,680 (97.7) 222 (99.1) 0.450 1095 (98.2) 221 (99.1) 1.000
Missing 284 (0.5) 0 6 (0.5) 0
Duration of admission (IQR) 13 (37.0) 17 (39.0) 0.101 12 (36.0) 17 (39.0) 0.027
Discharge destination, n (%)
NHS bed 3969 (6.5) 38 (17.0) <0.0001 53 (4.8) 38 (17.0) <0.0001
Care home 6390 (10.5) 14 (6.3) 0.037 97 (8.7) 14 (6.3) 0.287
Home/sheltered 39,125 (64.1) 114 (50. 9) <0.0001 765 (68.6) 113 (50.7) <0.0001
Other 782 (1.3) 4 (1.8) 0.541 19 (1.7) 4 (1.8) 1.000
Died 9694 (15.9) 51 (22.7) 0.008 160 (14.4) 51 (22.9) 0.002
Missing 1127 (1.8) 3 (1.3) 21 (1.9) 3 (1.3)
Death at end follow-up 33,169 (54.3) 192 (85.7) <0.0001 590 (52.9) 191 (85.7) <0.0001
ADL, activities of daily living; AF, atrial ﬁbrillation; CeVD, Cerebrovascular Disease; IHD, ischemic heart disease; IQR, interquartile range; IS, ischemic stroke; NHS, National Health
Service.
aStandardized difference: difference in means or proportions divided by SE; imbalance defined as absolute values >0.20.
Data are presented as no. (%).
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Table 5. Demographics, presentation, management, and outcomes after stroke from the Scottish Stroke Care Audit showing data before and
after propensity score matching for individuals with a renal transplant
Variable
Non-ESRD population
(n [ 61,087)
Kidney transplant
(RT) population
(n [ 56)
Standardized
differencea/P value
Propensity-matched
non-ESRD population
(n [ 280)
Propensity-matched
RT population
(n [ 56)
Standardized
differencea/P value
Patient demographics
Age, yr, median (IQR) 76 (17.0) 65.5 (15.0) 0.99 66 (15) 65.5 (15.0) 0.12
Female 31,368 (51.4) 21 (37.5) 0.28 101 (36.1) 21 (37.5) 0.03
Rural 10,015 (16.4) 6 (10.7) 0.17 22 (7.9) 6 (10.7) 0.10
Deprived 29,709 (48.6) 30 (53.6) 0.10 156 (55.7) 30 (53.6) 0.04
Previous AF 5019 (8.2) 4 (7.1) 0.05 12 (4.3) 4 (7.1) 0.12
Previous CeVD 3555 (5.8) 5 (8.9) 0.11 27 (9.6) 5 (8.9) 0.02
Previous IHD 12,025 (19.7) 15 (26.8) 0.15 79 (28.2) 15 (26.8) 0.03
Previous hypertension 25,818 (42.3) 41 (73.2) 0.63 207 (73.9) 41 (73.2) 0.02
Prior diabetes 8536 (14.0) 20 (35.7) 0.51 101 (36.1) 20 (35.7) 0.01
Case mix
Independent in ADLs before admission 47,184 (77.2) 41 (73.2) 0.692 236 (84.3) 41 (73.2) 0.597
Missing 5109 (8.4) 9 (16.1) 19 (6.8) 9 (16.1)
Living alone before admission 22,065 (36.1) 12 (21.4) 0.072 85 (30.4) 12 (21.4) 0.397
Missing 4453 (7.3) 9 (16.1) 18 (6.4) 9 (16.1)
Talking at ﬁrst assessment 42795 (70.1) 37 (66.1) 1.000 218 (77.9) 37 (66.1) 0.322
Missing 3707 (6.1) 7 (12.5) 14 (5.0) 7 (12.5)
Orientated at ﬁrst assessment 35,846 (58.7) 30 (53.6) 1.000 194 (69.3) 30 (53.6) 0.214
Missing 5325 (8.7) 10 (17.9) 18 (6.4) 10 (17.9)
Able to lift arms at ﬁrst assessment 35,622 (58.3) 37 (66.1) 0.052 187 (66.8) 37 (66.1) 0.486
Missing 4817 (7.9) 8 (14.3) 18 (6.4) 8 (14.3)
Able to walk on ﬁrst assessment 23,732 (38.9) 26 (46.4) 0.111 128 (45.7) 26 (46.4) 0.638
Missing 5529 (9.1) 8 (14.3) 21 (7.5) 8 (14.3)
Index stroke
Ischemic 51,606 (84.5) 52 (92.9) 242 (86.4) 52 (92.9)
Hemorrhagic 6954 (11.4) 4 (7.1) 30 (10.7) 4 (7.1)
Missing 2527 (4.1) 0 0.405 8 (2.9) 0 0.477
Admission source
Acute hospital 1984 (3.3) 0 0.426 11 (3.9) 0 0.223
Sheltered/care home 2758 (4.5) 0 0.180 8 (2.9) 0 0.362
Home 54,613 (89.4) 54 (96.4) 0.009 255 (91.1) 54 (96.4) 0.032
Rehab/other 904 (1.5) 0 1.000 2 (0.7) 0 1.000
Missing 828 (1.4) 2 (3.6) 4 (1.4) 2 (3.6)
Management
Admitted to stroke unit 47,619 (78.0) 44 (78.6) 0.868 221 (78.9) 44 (78.6) 0.712
Missing 1415 (2.3) 0 7 (2.5) 0
Thrombolysis: IS only 2487 (4.8) 3 (5.8) 0.731 8 (3.3) 3 (5.8) 0.407
Missing 25,009 (40.9) 26 (46.4) 119 (42.5) 26 (46.4)
Aspirin: IS only 43,194 (83.7) 38 (73.1) 0.051 200 (82.6) 38 (73.1) 0.157
Missing 601 (1.0) 1 (1.8) 3 (1.1) 1 (1.8)
Swallow screen 48,692 (79.7) 41 (73.2) 0.457 222 (79.3) 41 (73.2) 0.565
Missing 2519 (4.1) 4 (7.1) 9 (3.2) 4 (7.1)
Brain imaging 59,680 (97.7) 56 (100.0) 0.629 276 (98.6) 56 (100) 1.000
Missing 284 (0.5) 0 4 (1.4) 0
Duration of admission (IQR) 13 (37) 11 (32) 0.683 11 (22) 11 (32) 0.541
Discharge destination
NHS bed 3969 (6.5) 4 (7.1) 0.784 16 (5.7) 4 (7.1) 0.756
Care home 6390 (10.5) 1 (1.8) 0.027 15 (5.4) 1 (1.8) 0.488
Home/sheltered 39,125 (64.1) 39 (69.6) 0.479 214 (76.4) 39 (69.6) 0.292
Other 782 (1.3) 0 1.000 3 (1.1) 0 1.000
Died 9694 (15.9) 11 (19.6) 0.462 26 (9.3) 11 (19.6) 0.034
Missing 1127 (1.8) 1 (1.8) 6 (2.1) 1 (1.8)
Death at followup 33,169 (54.3) 37 (66.1) 0.082 117 (41.8) 37 (66.1) 0.001
ADL, activities of daily living; AF, atrial ﬁbrillation; CeVD, Cerebrovascular Disease; IHD, ischemic heart disease; IQR, interquartile range; IS, ischemic stroke; NHS, National Health
Service.
aStandardized difference: difference in means or proportions divided by SE; imbalance defined as absolute values >0.20.
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Table 6. Baseline demographics of all end-stage renal disease
patients, alive versus dead at end of follow-up
Variable Alive (n [ 4136) Dead (n [ 4621) P value
Age at ﬁrst RRT, yr, median (IQR) 44.6 (27.0) 67 (20.8) <0.0001
Sex
Female 1743 (42.1) 1932 (41.8)
Male 2393 (57.9) 2689 (58.2) 0.761
Primary renal diagnosis group
Missing 1 (0.02) 11 (0.2)
Glomuleronephritis 989 (23.9) 613 (13.3) <0.0001
Interstitial disease 1403 (33.9) 904 (19.6) <0.0001
Multisystem 613 (14.8) 1181 (25.6) <0.0001
Diabetic nephropathy 540 (13.1) 1045 (22.6) <0.0001
Other 590 (14.3) 867 (18.8) <0.0001
Urban-rural
Rural 722 (17.5) 733 (15.9)
Urban 3414 (82.5) 3888 (84.1) 0.047
SIM
Least deprived 3080 (74.5) 3405 (73.7)
Most deprived 1056 (25.5) 1216 (26.3) 0.407
Medical history
Atrial ﬁbrillation 76 (1.8) 478 (10.3) <0.0001
Ischemic heart disease 743 (18.0) 1952 (42.2) <0.0001
Stroke 60 (1.5) 260 (5.6) <0.0001
Diabetes 935 (22.6) 1726 (37.4) <0.0001
Hypercholesterolemia 423 (10.2) 710 (15.4) <0.0001
Obesity 201 (4.9) 294 (6.4) 0.004
HBP 2887 (69.8) 3368 (72.9) 0.017
Clinical variables, median (IQR)
Systolic BP, mm Hg 138.0 (27.0) 138.5 (31.5) 0.755
Diastolic BP, mm Hg 75.0 (17.0) 69.0 (19.0) <0.0001
Weight, kg 75.2 (23.0) 70.3 (22.3) <0.0001
Laboratory variables
Hemoglobin, g/l 12 (2.0) 11.3 (1.8) <0.0001
Albumin, mmol/l 39 (6.0) 36 (7.0) <0.0001
Serum phosphate, mmol/l 1.21 (0.6) 1.45 (0.6) <0.0001
Adjusted calcium, mmol/l 2.38 (0.2) 2.36 (0.2) <0.0001
ESA use
Stroke during study period 53 (1.3) 433 (9.4) <0.0001
ESA, erythropoietin-stimulating agent; BP, blood pressure; HBP, high blood pressure;
IQR, interquartile range; RRT, renal replacement therapy; SIMD, Scottish Index of
Multiple Deprivation.
Data are presented as no. (%).
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Individuals with ESRD were less likely to be inde-
pendent in activities of daily living (63.8% vs. 78.6%;
P < 0.0001) and less likely to be living alone (22.9%
vs. 30.8%; P ¼ 0.025) before admission. There were
similar results found in individuals on dialysis, but
there were no signiﬁcant differences between in-
dividuals with a kidney transplant and the non-ESRD
stroke population (Tables 3–5).
Output After PSM: Admission Source
Individuals with ESRD and individuals treated with
dialysis were more likely to present with stroke from
an acute hospital rather than from home (7.5% vs.
2.2%; P < 0.0001 and 9.4% vs. 2.4%; P < 0.0001,
respectively). Transplant recipients were more likely to
be admitted from home (96.4% vs. 91.1%; P ¼ 0.032)
compared with the non-ESRD stroke population
(Tables 3–5).
Output After PSM: Stroke Care and Audit
Standards
Individuals with ESRD and individuals treated with
dialysis were less likely to be managed on an acute
stroke unit during their admission (67.4% vs. 79.6%;
P < 0.001 and 64.6% vs. 79.6%; P < 0.001, respec-
tively) and less likely to receive aspirin (74.8% vs.
83.6%; P ¼ 0.002 and 75.3% vs. 83.2%; P ¼ 0.01,
respectively). There were no differences in manage-
ment of transplantation recipients compared with the
non-ESRD stroke population (Tables 3–5).
Individuals on dialysis were less likely to be
admitted to a stroke unit on day 0 or 1 (43.5% vs.
62.6%; P ¼ 0.005), less likely to have a swallow screen
within the ﬁrst 24 hours (66.4% vs. 74.1%; P ¼ 0.017),
and less likely to receive thrombolysis within 60
minutes (1.5% vs. 3.9%; P ¼ 0.016). These measures
did not differ in kidney transplantation recipients
(Supplementary Tables S6–S8).
PSM: Discharge Destination
Individuals with ESRD and individuals on dialysis
were more likely to remain in an National Health
Service inpatient bed (15.1% vs. 4.7%; P < 0.0001 and
17.0% vs. 4.8%; P < 0.0001, respectively) and were
less likely to be discharged to home or to a sheltered
accommodation (54.5% vs. 70.2%; P < 0.0001 and
50.7% vs. 68.6%; P < 0.0001). This association was not
present in individuals with a kidney transplant. In
both dialysis and kidney transplant patients, in-
hospital mortality was almost double the rate demon-
strated in individuals without ESRD (dialysis: 22.9%
vs. 14.4%; P ¼ 0.002; transplant: 19.6% vs. 9.3%;
P ¼ 0.034).
Kidney International Reports (2018) 3, 1064–1076ESRD Mortality After Stroke
At end of follow-up, 4621 (52.8%) individuals with
ESRD had died. Death was more likely in individuals
who were older, who had high cardiovascular comor-
bidity burden, and who experienced stroke during
follow-up. Further demographics are presented in
Table 6.
A total of 229 (81.8%) of the 280 individuals with
ESRD who experienced stroke died compared with
33,169 (54.3%) of 61,087 individuals in the general
stroke population. The higher mortality rate remained
after PSM (85.7% vs. 52.9% for dialysis; P < 0.0001
and 66.1% vs. 41.8% for transplant; P ¼ 0.001)
(Tables 4 and 5).1071
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in individuals on dialysis, 2.5 (3.8) years in individuals
with a kidney transplant, and 3.1 (4.4) years in the non-
ESRD stroke population (P < 0.0001) (Figure 1 and
Supplementary Figure S3, demonstrating split by RRT
modality).
When we assessed all stroke episodes in both ESRD
and non-ESRD populations, there was demonstrably
lower survival in individuals with ESRD than those
without ESRD. Furthermore, the presence of ﬁrst
recorded stroke episode during follow-up within the
SMR01 was associated with lower survival than those
recorded within the SSCA (Figure 2).
In individuals with ESRD alone, 157 (35.0%) pa-
tients with a ﬁrst recorded stroke were admitted to a
stroke unit. At follow-up, mortality was lower in those
admitted to a stroke unit (82.8% vs. 91.1%; P ¼ 0.014).
On multivariable analysis, admission to a stroke unit
was associated with lower risk of death (hazard ratio:
0.68; 95% conﬁdence interval: 0.550.84; P < 0.001)
(Figure 3 and Supplementary Table S9).DISCUSSION
In this population-based record linkage cohort study we
demonstrated that incidence of stroke in ESRD is high
and higher in individuals receiving dialysis compared
with kidney transplant recipients. We found in-
dividuals with ESRDwho experienced stroke were more
functionally dependent at presentation, there were dif-
ferences in delivery of stroke care to individuals with
ESRD, and in-hospital death from stroke was higher.
These ﬁndings suggest that provision of stroke care for
individuals with ESRD needs urgent review.
The stroke rate of 25.3 and 4.5 per 1000 patient-years
in individuals on dialysis or transplant recipients,Figure 1. Kaplan-Meier estimator survival curves demonstrating time to d
disease (ESRD), transplant recipients. and dialysis patients. Log-rank test
1072respectively, is in keeping with previous published re-
ports.8,20,22,23 During the same period, the crude inci-
dence rate for cerebrovascular disease in Scotland was
2.4 per 1000 patient-years,24 which demonstrated a 10-
fold increase in stroke incidence in individuals who
received dialysis. In real-world terms, in our renal unit,
with prevalent population of approximately 650 dialysis
recipients, this equated to 1 stroke every 22 days or,
nationally, 1 stroke per week.
Stroke Incidence and Presentation
Individuals on dialysis were functionally more depen-
dent at presentation than theirmatchednon-ESRD stroke
population cohort. Functional dependence is common in
ESRD25 and is an independent predictor of mortality.26
Patients who received dialysis were more likely to be
admitted from an acute hospital than home. There were
possible explanations for this. Primarily, there is an
increased likelihood of hospitalization with ESRD27 but
also a temporal relationship between dialysis itself and
stroke.28 In one single-center study, 39.5%of infarctions
and 34.7% hemorrhages occurred during or within 30
minutes of completing dialysis. It is likely that such
strokes would initially be referred to nephrology.
Inequalities in Care
As well as being less likely to be managed in acute
stroke units, individuals with ESRD treated with dial-
ysis were less likely to undergo a swallow test within
the ﬁrst 24 hours, less likely to receive aspirin on arrival
to hospital, and less likely to receive prompt throm-
bolytic therapy. Interestingly, this pattern of care was
not seen in renal transplant recipients. Differences in
care after myocardial infarction in ESRD are previously
demonstrated, but these differences were attributed to a
lack of an accurate diagnosis at ﬁrst assessment due toeath after stroke in the matched population without end-stage renal
; P < 0.0001.
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Figure 2. Kaplan-Meier survival curves demonstrating time to death after following stroke in both end-stage renal disease (ESRD) and non-
ESRD populations, split by source of stroke diagnosis: non-ESRD Scottish Stroke Care Audit (SSCA), non-ESRD Scottish Morbidity Records
01 (SMR01), ESRD population SSCA, and ESRD population SMR01. Log-rank test; P < 0.0001.
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graphic changes.12 In our cohort, presenting symptoms
were similar between groups; therefore, so we believe
delayed recognition of stroke did not explain the dif-
ferences. It is possible that practical considerations
surrounding need for dialysis make stroke unit care
impractical or unattractive. In a survey of nephrologists
it was felt that adverse effects of dialysis schedules,
coupled with lack of stroke unit care might negatively
affect recovery and would require future attention.16
An alternate explanation was that specialist stroke
units might feel uncomfortable caring for dialysis pa-
tients and elect not to transfer care.Figure 3. Kaplan-Meier survival curves demonstrating time to death afte
admission to an acute stroke unit (ASU). Log-rank test P < 0.0001.
Kidney International Reports (2018) 3, 1064–1076Only 280 of 486 strokes that occurred in individuals
with ESRD were included in the SSCA data set. It is
believed that the SSCA most accurately represents the
number of strokes occurring in Scotland.29 It is
acknowledged that omission of strokes from the SSCA
can occur if the patient was in hospital at the time of
stroke or was not referred promptly to stroke services.
Such a high number of strokes not recorded in the SSCA
was unexpected and suggested substantial inequality in
access to gold standard stroke care for individuals with
ESRD. A recent paper that addressed selection bias after
stroke demonstrated consistent improvement up to 1
year after stroke from use of stroke units.17 We exploredr stroke in patients with end-stage renal disease and the effect of
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to a stroke unit as a marker of optimal stroke care. In-
dividuals with ESRD admitted to a stroke unit had a
signiﬁcantly lowermortality rate at follow-up than those
who were not admitted. It must be acknowledged this
might be in part related to selection bias at the time of
stroke; those more severely affected at presentation
might not be referred onward.
Discrepancies in Mortality
Mortality after stroke is declining in general population
studies,30 but we found striking differences in mortality
rates — both during stroke admission and on longer
follow-up. This extended to individuals with ESRD and
a kidney transplant who were twice as likely to die on
their initial admission and had higher mortality rates at
follow-up. Because our matching process controlled for
hypertension, diabetes, and ischemic heart disease, an
accrued risk speciﬁc to CKD not reversed by trans-
plantation seems a likely explanation. This is an
important ﬁnding because transplant recipients with
normal range serum creatinine could be overlooked as
having a lower risk. Unfortunately, creatinine values
were not available in our non-ESRD population data.
Finally, we detected signiﬁcant differences in sur-
vival based on diagnosis source; higher survival
occurred in individuals diagnosed via SSCA compared
with individuals in the SMR01, and there was higher
survival in those admitted to a stroke unit. These ﬁnd-
ings support the conclusion that specialist stroke care
was associated with a lower mortality rate in individuals
with ESRD. Although this may be related to therapeutic
nihilism in cases of more severe stroke, we could not
provide data to support this. Therefore, serious consid-
eration must be paid to the merits of managing stroke on
a renal ward for reasons of dialysis practicalities alone.
Strengths and Limitations
Linkage of national data sets provided a large population
with unique results that demonstrated issues relevant to
patient care. Our main strengths included large numbers
of patients in both ESRD and stroke populations. Scot-
land is broadly representative of both European
nephrology and stroke care in terms of patient de-
mographics and outcomes for both conditions.31,32
Furthermore, the granularity of data allowed descrip-
tion of the stroke pathway from presentation to
discharge, use of death records allowed a follow-up
period, and since 2005, both the SRR and SSCA have
been all-inclusive data sets. We supported complete
capture by accessing the SMR01 data set. Despite these
strengths, we acknowledge limitations. First, all data
were retrospective, and therefore, we could not prove
causation, only describe associations. Because it was not1074feasible to study the primary outcome of our study—
impact of ESRD on outcomes after stroke—in a ran-
domized fashion, we addressed the retrospective nature
of the data by performing PSM. Second, missing data
limited the ability to fully exclude other factors that
inﬂuenced outcome. For instance, we lacked markers of
stroke severity (e.g., National Institutes of Health Stroke
Scale) because this was only recorded when thrombol-
ysis was used. Finally, discrepancies in survival after
stroke split by diagnosis source warrants attention. Se-
lection bias could result in frailer, sicker patients
bypassing the stroke unit (and omission from the SSCA)
following deterioration on dialysis. Nonspecialist input
might result in misdiagnosis. However, internal valida-
tion of SMR01 coding conﬁrmed the approximately 90%
accuracy rate,33 making this unlikely.
CONCLUSIONS
Stroke is common in individuals with ESRD with poor
outcomes. Individuals on dialysis are functionally more
dependent at presentation and are less likely to be
managed on a stroke unit. Individuals with a renal
transplantation are similar at presentation and provided
with equivalent care to the general population, but
retain a signiﬁcantly higher mortality rate. ESRD should
not exclude individuals from ideal care after stroke, and
efforts should be made to deliver such care to all.
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